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reported among the elderly (74.21%), significant variations across age groups, re-
gions, and insurance types observed in this well-insured group call for future re-
search to better understand reasons behind these variations.
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OBJECTIVES: In Japan, the screening rates for breast and cervical cancers have been
lower than in other countries, with rates below 20%. Breast cancer screening has
been conducted biennially for over 40 years, and cervical cancer screening has been
conducted biennially for over 20 years. Since lack of resources is an important
barrier to increasing cancer screening rates, relationships between resources and
cancer screening rates were investigated for breast and cervical cancers in Japan.
METHODS: Based on the national data from 2008, the resource gap among 47
prefectures was compared. Resources were defined by the number of mammogra-
phy equipment installations (per 100,000 women) for breast cancer screening and
the number of gynecologists (per 100,000 women) for cervical cancer screening.
Correlations between the screening rates and the availability of resources were
calculated. RESULTS: The national average breast cancer screening rate was 14.7%,
varying from 2.5% to 35% among the 47 prefectures. The national average number
of mammography equipment installations was 5.88 per 100,000, ranging from 8.81
to 4.41 per 100,000 among the 47 prefectures. The correlation between mammog-
raphy equipment installations and the screening rate for breast cancer was 0.420
(P0.01). The national average cervical cancer screening rate was 19.4%, varying
from 12.1% to 34.8% among the 47 prefectures. The national average number of
gynecologists was 18.0 per 100,000, ranging from 13.1 to 25.9 per 100,000 among the
47 prefectures. The correlation between the number of gynecologists and the cer-
vical cancer screening rate was -0.079 (n.s). CONCLUSIONS: Although the breast
cancer screening rate shows a close relationshipwithmedical resource availability,
there is no relationship for cervical cancer screening. Since medical resources to
increase breast cancer screening are limited in local areas, sufficient resources
should be provided. In cervical cancer screening, other factors that affect the
screening rate should be investigated.
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OBJECTIVES: Non-participation by potential study subjects in population research
can affect the validity and generalizability of study outcomes. The study objectives
were to evaluate the differences between participants and non-participants who
were targeted for enrollment in the Bonnie’s Bus Mobile Mammography Program
(BBMMP) conducted throughout West Virginia, and to determine the predictors of
willingness to participate in future research among those who consented to pro-
vide initial surveillance data. METHODS: Data collected from 2441 women who
were screened in the BBMMP were analyzed using the chi-square test and logistic
regression. RESULTS: Of the 2441 women who were screened by BBMMP over a 3
year period, 1178 women (48.3%) chose not to consent to participate in the surveil-
lance study. Bivariate analysis indicated that being over 65 years, single, over-
weight, uninsured, unemployed, or of minority race were associated with non-
enrollment in the study. The multivariate adjusted model indicated that being of
age 65 years and above (AOR2.10), being single (AOR1.25), or being from a mi-
nority race (AOR1.97) were significant predictors of non-participation. Of the
1,263 women who consented to participate in the study and provided surveillance
data, 407 women (32.2%) declined to being contacted for participation in future
breast cancer screening research. The unadjustedmodel showed that womenwho
have breast problems, are adherent to mammography screening guidelines, and
aremarried/partnered aremore likely to bewilling to participate in future research.
Multivariate logistic regression analysis revealed that women adherent to mam-
mography screening guidelines are more likely to agree (AOR1.40) to participate
in future research than non adherent women. CONCLUSIONS:Women who are at
risk for breast cancer and who are likely targets for interventions to increase ad-
herence to mammography screening guidelines are more likely to not participate
in breast cancer screening studies than those who may not be at risk and are
adherent to screening guidelines.
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OBJECTIVES: Few studies have focused on access to care for women through utili-
zation of a mobile mammography unit. Bonnie’s Bus Mammography Mobile Pro-
gram (BBMMP) was created to provide mammograms to women in rural areas
throughout West Virginia (WV) and surrounding areas. Based on a 3-year analysis
of the data, 80.4% of its clientele had a BMI of 30 or above as compared to 64.9% for
all WV women age 40 and above. Thus, the objectives of the study were to: 1) to
describe the demographics and comorbidities of womenwho utilized BBMP, and 2)
to determine the association between BMI and personal health and screening his-
tory, preventive care, and wellness behaviors. METHODS: Three years BBMP sur-
veillance data collected from 1099 women age 40 and above were analyzed. BMI by
personal health and screening history, preventive care, wellness behaviors, and
demographics were analyzed using descriptive statistics, chi-square tests, and a
linear regression model. RESULTS: Women were mostly married (60.4%), had
health insurance (53.2%), were employed (46.5%), and had an annual income be-
tween $10,000-25,000 (40.9%). Major comorbidities were hypertension (49%) and
high cholesterol (43.9%). Increasing BMI was associated with greater likelihood of
thyroid disease, hypertension, diabetes, high cholesterol, allergies, hormone re-
placement therapy use, activity limitations, perceived weight problem, lower ex-
ercise, inability to getmedications due to cost, lower doctor visits, and being single.
Those with lower BMI were less likely to smoke or drink alcohol. The regression
model was significant (F13.729, p0.001, R2  0.412) and indicated that women
who engaged in preventive care behaviors were less likely to be obese than those
who did not. CONCLUSIONS: The BBMMP attracted women who were dispropor-
tionately obese and had multiple co-morbidities, thus providing a great opportu-
nity for targeted interventions related to improving preventive care, screening, and
self-care behaviors.
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OBJECTIVES: Specialty pharmacy programs are increasingly used to improve the
quality of outpatient therapy with oral medications for cancer. We evaluated
whether use of particular specialty pharmacy services is associated with improved
oncology medication use and reduced overall healthcare costs, as compared to
retail pharmacy services. METHODS: The study is a retrospective claims analysis
post implementation of a specialty pharmacy program, by a national commercial
payer. A matched sample of patients assigned to use specialty pharmacies and
those who used retail pharmacies for oral cancer therapies were compared. Pri-
mary outcomes were financial, including overall health care costs, outpatient
costs, medical costs, and pharmacy costs. Outcomes one year post-implementa-
tion in specialty pharmacy users and retail pharmacy controlswere comparedwith
t-tests for continuous variables, chi-square for nominal variables, and logistic re-
gression for matching. Propensity scores were used to adjust for unmeasured con-
founding in the groups. RESULTS: The final analysis included 464 patients per
cohort. The mean total costs per patient was 13% lower in the specialty pharmacy
group ($84,105 vs. $97,196; difference  $-13,092; P  0.02) in the follow-up period.
The mean outpatient hospital costs ($16,777 vs. $28,629, difference  $-11,852; P 
0.01) were lower in the specialty group by 41%, with an associated significant dif-
ference in outpatient hospital visits (15.75 vs. 19.66, P  0.01). Patients in the spe-
cialty pharmacy groupweremore adherent to therapy, MPR 0.73 vs. 0.66, (P 0.01).
CONCLUSIONS: This specialty pharmacy program implemented by a national
commercial payer appears to improve oral oncology medication adherence and
decrease overall health care costs, mainly by impacting outpatient hospital utili-
zation.
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OBJECTIVES: The rising costs of cancer care have caused concerns regarding the
increasingOOP burden on cancer patients. The objective of this study is to examine
patients’ OOP expenditures on G-CSF, pegfilgrastim and filgrastim, two supportive-
care agents for cancer patients treated with myelosuppressive chemotherapy.
METHODS: Two large US health care claims databases (2008-Q2 2010 MarketScan®
Commercial and Medicare Supplemental Databases, and 2007-Q2 2009 HealthCore
Integrated Research DatabaseSM) were used to identify adult patients receiving
chemotherapy and G-CSF in outpatient settings. The summary statistics of quar-
terly OOP costs were tabulated for patients with any G-CSF claim for each quarter
during Q1 2007-Q2 2010. Costs were adjusted to June 2010 dollars. RESULTS: The
pattern of patients’ OOP costs for G-CSF was generally consistent between the two
data sources and over time. On average, about 65-75% of patients on G-CSF in-
curred zero OOP costs in a quarter. Across the years, the average quarterly OOP
costs per patient for all patients ranged from $100-$150 for pegfilgrastim and $50-
$100 for filgrastim.When focusing on the 20,948 patients onG-CSFwith continuous
health plan enrollment throughout 2009 in MarketScan®, mean OOP costs/patient/
quarter were $100 for pegfilgrastim and $53 for filgrastim. On average 69.2% of
pegfilgrastim patients and 63.9% of filgrastim patients had zero OOP costs in a
quarter. Very few patients (5.5% of pegfilgrastim and 2.7% of filgrastim) had quar-
terly OOP costs reaching $500 or above. The subgroup of patients with $0 quar-
terly OOP costs had mean costs/patient/quarter that were $324 for pegfilgrastim
and $146 for filgrastim. During 2009, that subgroup had an average of 2.4 adminis-
trations and/or prescriptions per quarter for pegfilgrastim and 5.5 for filgrastim.
The mean OOP costs of those administrations and/or prescriptions were $128 for
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pegfilgrastim and $30 for filgrastim. CONCLUSIONS: During 2007-2010, the major-
ity of patients did not pay OOP for G-CSF.
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ENGLAND
Kilby S
Surrey, West Sussex and Hampshire Cancer Network, Guilford, Surrey, UK
OBJECTIVES: In 2010 the UK government made an election pledge to improve ac-
cess to cancer drugs. The Interim Cancer Drugs Fund (ICDF) was introduced in
October 2010. This became the Cancer Drugs Fund (CDF) in April 2011. An addi-
tional £200 million per year, for three years was made available to fund cancer
drugs within England. The CDF money was allocated to the 10 Strategic Health
Authorities within England. The Cancer Network Pharmacists manage or are
closely involved with the CDFs. The objective of this research was to identify the
impact on oncology drug use and healthcare resources as a result of the introduc-
tion of the CDF. METHODS: A literature search was undertaken to identify any
research relevant to the CDF, cancer drug and healthcare resource use. A semi
structured questionnaire developed to capture quantitative and qualitative data
relating to changes in oncology drug use and healthcare resources. The question-
naire was piloted with three Cancer Network Pharmacists. Telephone interviews
were undertaken with Network Pharmacists covering the ten CDFs. The data col-
lected was assessed and evaluated, using a thematic framework. The results of the
researchwere then validated by three Cancer Network Pharmacists. RESULTS: The
CDF had led to a significant increase in use of some drugs, hospital attendances,
associated treatment costs and workload for Network Pharmacists. The commis-
sioning process for cancer drugs had changed; new drugs were not commissioned
unless recommended by NICE. CONCLUSIONS: The CDF had changed clinical prac-
tice for the management of certain cancers. The Increased use of cancer drugs had
led to additional costs which were not covered by the CDF. If the CDF disappeared
in 2014 it was unclear how some drugs would be funded which would have impli-
cations for clinical practice.
PCN133
DATA LINKAGE FOR HPV VACCINATION, SCREENING, AND CERVICAL CANCER
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OBJECTIVES: To assess the availability of linked data on HPV vaccination, screen-
ing, and cervical cancer outcomes to guide public health decision-making on cer-
vical cancer prevention strategies. METHODS: MEDLINE and Google Scholar (1/1/
2006-12/31/2011) were searched using keywords HPV registry, linkage, and cervical
cancer to identify countries with national HPV vaccination. Australia, New Zea-
land, Denmark, Norway, Greenland, Sweden, Iceland, the United Kingdom, Can-
ada, Mexico, and the United States were selected for detailed analysis based on
previous review frameworks (Wong et al. 2010; Sander et al. 2012). Information on
infrastructure, outcomes collected, surveillance registries and data linkage for
these countries through January 15, 2012was extracted from official health author-
ity websites and government reports. Documents not publicly available or without
data on these topics were excluded. RESULTS: Twenty peer-reviewed articles and
health authority documents were selected for review. Of the 11 countries evalu-
ated, 64% (7/11) have national HPV vaccination registries collecting vaccination
data and comprehensive cancer registries that include cervical cancer outcomes.
Four out of the eleven participate in theWHOHPV Laboratory Network that aims to
develop an international reference system for HPV assays to monitor performance
ofHPVvaccines. Five of the 11 countries have linkage of vaccination, cancer screen-
ing, and cancer registry records at the national level; however, the other six coun-
tries have potential linkages at provincial/territorial levels. None of the 11 coun-
tries had data on HPV DNA genotyping linked with other cervical cancer screening
and vaccination data. CONCLUSIONS: While fewer than half of the countries as-
sessed had nationally linked data on HPV vaccination, screening, and cervical can-
cer outcomes, the remaining countries have potential local-level linkages of these
data. Establishing data linkages across these sources of information can enable an
evidence base to explore the impact of national vaccination strategies and to in-
form cervical cancer prevention efforts.
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EFFECTS OF CLINICAL PHARMACIST INTERVENTIONS ON CLINICAL OUTCOMES
IN ONCOLOGY PATIENTS
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OBJECTIVES: To assess the effect of clinical pharmacist interventions on the clin-
ical outcomes in oncology patients. METHODS: A total of 100 patients received
their chemotherapy cycles with clinical pharmacy interventions were enrolled in
the present study during January 2007 to January 2008. Clinical pharmacy interven-
tions include: Detecting medication errors by using a modified form of the Ameri-
can Society of Hospital Pharmacists (ASHP) worksheet. Correcting those errors and
sending recommendations to the medical staff. RESULTS: The clinical pharmacy
interventions reduced the number ofmedication errors from1548 to 444whichwas
statistically significant (p0.004). A total of 1104 clinical pharmacy interventions
were documented in this present study. Forty-five percent of clinical pharmacy
interventions have led to increase in the efficacy of chemotherapy regimen and
54.7% have led to decrease in the chemotherapy toxicity. Seventy six percent of the
errors recorded in the present study occurred in the prescribing stage, about 20% in
the administration stage and 3.8% in the dispensing stage. CONCLUSIONS: The
clinical pharmacy interventions among oncology patients can reduce the number
of medication errors; improve the clinical outcomes through increasing chemo-
therapy efficacy and reducing the toxicity.
PCN135
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OBJECTIVES: The objective of this study is to determine how 25 major private US
payers use approved compendia and treatment guidelines when creating oncology
coverage policy for product usage outside of Food and Drug Administration (FDA)
approved indications.METHODS: Primary and secondary research was conducted
on the oncology coverage policies of US payers, n25, to determine if they follow
the Centers for Medicare & Medicaid Services (CMS) recommended guidelines on
use of compendia when making coverage policy decisions. Payer polices reviewed
include: United, Anthem, PacifiCare, Empire BC/BS, CIGNA, BC/BS of AB, Oxford,
BC/BS of TN, Kaiser, Humana, BC/BS of IL, CareSource, BC/BS of NC, CareFirst,
Wellpoint, BC/BS ofMN,Highmark, Aetna, GoldenRule, BC/BS ofMI, Independence,
BC/BS of FL, BC/BS of MA, BC/BS of WA, BC/BS of TX. RESULTS: Of the 25 US payers
surveyed, 12 payers follow CMS published guidelines that now mandate that cov-
erage can be given if an indication has a positive review in one of the approved
compendia and as long as no one compendia has a negative listing of the indica-
tion. A total of 8 payers have authored unique coverage policies that often are
broader than CMS’ guidelines. Such policies often include coverage for indications
listed in the National Comprehensive Cancer Center (NCCN) Drug & Biologics Com-
pendia as class IIb or III. The remaining five payers continue to rely on CMS’ previ-
ous policy prior to the expansion of the compendia list. CONCLUSIONS: The ma-
jority of the 25 US private payers surveyed have oncology coverage policies for non
FDA indicated uses that either mirror CMS’ compendia policy, or are somewhat
more liberal in their interpretation based on their review of published data and
reliance on lower levels of evidence.
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OBJECTIVES: To understand relative price differential for cancer drugs in the
United States and the United Kingdom. Develop implications for pricing strategy
and patient access for cancer drugs. METHODS: Ten branded cancer drugs were
selected and their prices for similar dose and packaging were compared in the
United States and the United Kingdom. Prices were analyzed for the end of 2010
and early 2011. Historical exchange rateswere used to convert British pounds to US
dollars. Relative price discount was calculated for all selected cancer drugs. KOLs
and payers were interviewed to understand current and future implications of this
price differential. RESULTS: The median price discount for selected ten branded
cancer drugs in theUnitedKingdomversus theUnitted Stateswas50%. The range
of discount for 10 branded cancer drugs was 27%-61%. The price discount for oral
small molecule drugs was higher than for biologics (55% vs. 45%). Since United
Kingdom is one of the few remaining free pricing markets in Europe, other Euro-
pean markets are likely to have even higher discounts relative to the prices in the
United States. Due to rising coinsurance of speciality products, US cancer patients
bear significantly higher cost than patients in the United Kingdom. KOL and payer
interviews suggest US pricing trends for cancer drugs are unlikely to be sustained
at this level in the future. CONCLUSIONS: US cancer drug prices are significantly
higher than the prices in the United Kingdom. This price differential is unlikely to
be sustained in the future.
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METASTATIC MELANOMA
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OBJECTIVES: To describe treatment patterns with surgery, radiation, and systemic
(drug) therapies in patients with metastatic melanoma in the United States.
METHODS: Using a large US medical claims database, patients were identified
between 2005 and 2010 using 2 melanoma diagnoses (ICD-9-CM: 172.xx, V10.82)
and2 diagnoses formetastasis (ICD-9-CM: 197.xx, 198.xx). The index datewas the
first date of metastasis diagnosis. Patients were followed from the index date to
death, disenrollment, or end of the study period (6/30/2010), whichever occurred
first. Surgery, radiation, and systemic therapies were examined descriptively. Fac-
tors influencing treatmentwere examined using a logistic regression separately for
surgery, radiation, and systemic therapy. RESULTS: A total of 2546 patients with
metastatic melanoma were included in the analyses. Mean ( standard deviation)
age was 60.6 ( 14.0) years old with 22.8% under 50 and 36.5%were female. Overall,
66.8% of patients had cancer treatment related surgery, 38.7% received systemic
therapies, 44.7% received radiation, and 17.7% of patients received all three treat-
ments. Logistic regressions revealed that patients with lung (p 0.0001), brain (p
0.0001), liver (p 0.0001), or bone (p 0.0001) metastases were less likely to have
surgeries; patients with lung (p  0.04), brain (p  0.001), or liver metastases (p 
0.03) were more likely to receive systemic therapies; as expected patients with
brain (p  0.0001) or bone metastases (p  0.0001) were more likely to have radia-
tion therapy. Patients being treated by oncologists were more likely to receive
systemic therapy (p 0.0001) or radiation (p 0.0001) while patients being treated
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